Josh joined NEA in September 2004 as a Venture Partner. He works closely with NEA's healthcare team and focuses primarily on medical devices and pharmaceutical investments. Josh is also the Founder & Chief Executive Officer of ExploraMed II and III, Inc., both NEA portfolio companies created to be medical device incubators based on the West Coast. Acclarent, Inc, an ExploraMed II company, was acquired by Johnson & Johnson in 2009. NeoTract, Inc. (created by ExploraMed II) and Vibrynt, Inc. and Moximed, Inc. (created by ExploraMed III) are launched and independently funded. In addition, Josh serves a part-time role on the faculty of the Stanford University Medical School as a Consulting Associate Professor of Medicine and is Co-Director of Stanford’s Biodesign Innovation Program. Josh serves on the board of directors for ExploraMed II, ExploraMed III, Intrinsic Therapeutics, Inc., NeoTract, Inc. and Vibrynt, Inc. Prior to NEA, Josh was Founder, Chairman and Chief Technical Officer of TransVascular, Inc. (acquired by Medtronic, Inc. in 2003), and Founder and Chairman of EndoMatrix, Inc. (acquired by C.R. Bard in 1997.) Until 1995, Josh was Founder and Manager of Pfizer’s Strategic Innovation Group. Josh holds over fifty patents for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics and urology. He received an MBA from Columbia University, a medical degree from the New York University School of Medicine, and a bachelor's degree in Mechanical Engineering from the Massachusetts Institute of Technology.